Japan-based companies Toray Industries, Inc., and Meiji Seika Pharma Co., have obtained regulatory approval in Thailand to import and market REMITCH OD Tablets 2.5µg in the country. This medication is for hemodialysis patients finding existing cutaneous pruritus therapies and treatments ineffective.

REMITCH OD Tablets 2.5µg has been already marketed in Japan for dialysis patients and chronic liver disease sufferers similarly finding existing pruritus therapies and treatments ineffective.

In January 2019, Meiji Seika Pharma and Toray signed an agreement to develop and market this medicine in Thailand and Indonesia, thereafter developing it in those countries.

Thai Meiji Pharmaceutical filed an approval application with the Food and Drug Administration of Thailand’s Ministry of Public Health in April 2021. As well as marketing REMITCH OD Tablets 2.5µg in that nation, the company will also supply information about that medication. 

Through the marketing approval of REMITCH OD Tablets 2.5µg, Meiji Seika Pharma and Toray will offer hemodialysis patients across Thailand a new alternative for alleviating pruritus.

Toray developed REMITCH as the world’s first highly selective kappa opioid receptor agonist. People can take these orally disintegrating tablets with or without water, helping to enhance medication compliance among those with fluid restrictions.